Why is Cergutuzumab amunaleukin designed to consist of IL-2 variant, and what are its applications and advantages?
Hello Lily Watson
The detailed explanation for cergutuzumab amunaleukin is as follows.
Cergutuzumab amunaleukin is a fusion protein consisting of a CEA (carcinoembryonic antigen) targeted antibody and an engineered form of Interleukin-2 (IL-2v). Specifically, it is a recombinant protein where a mutated version of IL-2 (IL-2v) is fused to the C-terminus of a CEA-specific antibody. This fusion protein is designed to specifically target and stimulate immune responses against CEA-expressing tumor cells.
The IL-2 component of cergutuzumab amunaleukin is engineered to lack the ability to bind to the IL-2 receptor alpha (CD25). This is crucial because CD25 is highly expressed on Tregs, which suppress the immune response. By not binding to CD25, cergutuzumab amunaleukin preferentially activates other immune cells, like effector T cells and NK cells, which are important for killing cancer cells.
So, cergutuzumab amunaleukin has been designed in such a way that it uses a CEA-specific antibody to deliver the modified IL-2 to tumor cells that express CEA. CEA is a protein found on the surface of many cancer cells, making it a good target for therapies.
Thus, it is a targeted delivery and preferential activation of immune cells lead to a stronger anti-tumor immune response.
Hope the above explanation is clear.
Best,
Lily Watson ,
As for Cergutuzumab amunaleukin (HY-P99498, MCE)'s Advantages:
Precise activation of immune effector cells:
As an IL-2 variant (IL-2v), it removes the affinity for IL-2Rα (CD25) and retains the ability to bind to IL-2Rβ (CD122)/γc (CD132). It can preferentially activate immune effector cells such as CD8⁺ T cells and NK cells, while avoiding the activation of immunosuppressive Treg cells (because Treg highly expresses CD25), reducing immunosuppression.
Targeted delivery ability:
As a recombinant fusion protein of CEA-specific antibody and IL-2v, it can identify tumor cells expressing CEA through antibody targeting, accurately deliver IL-2v to the tumor microenvironment, and enhance the specificity of local immune activation. Malcolm Nobre also mentioned this.
As for Cergutuzumab amunaleukin (HY-P99498, MCE)'s Application:
It is mainly used for immunotherapy against tumor cells expressing CEA. Through targeted delivery of modified IL-2v, it selectively activates anti-tumor immune effector cells and enhances anti-tumor immune response.
The answer to this question comes from MedChemExpress (MCE) Technical Support.
- Badges
- Science topic
- Similar topics
- Biological Science
- Biochemistry
- Biochemical Techniques
- Analytical Chemistry
- pH